Accupril

Teva Pharmaceutical Industries Ltd. began shipment of its quinapril HCl tablets in 5 mg, 10 mg, 20 mg and 40 mg doses. The generic is manufactured pursuant to Ranbaxy's abbreviated new drug application and will be sold under a Teva label and marketed by Teva USA. Quinapril HCl tablets are the AB-rated generic equivalent of Parke-Davis' antihypertensive Accupril, with annual sales of approximately $555 million. The launch followed Teva's relinquishment of its 180-day marketing exclusivity for the drug after it was granted final approval in 2003.

Teva also received tentative approval for the sale of metformin HCl extended-release tablets, the generic version of Bristol-Myers Squibb's Glucophage for treatment of type 2 diabetes, with annual sales of approximately $27 million. It also was granted tentative approval for its ANDA for oxycodone HCl extended-release tablets in 10 mg, 20 mg and 40 mg doses. The drug is the AB-rated generic equivalent of Purdue Pharma's OxyContin for the management of moderate-to-severe pain.

Teva completed its cash acquisition of Pfizer's Italian generic drug arm, Dorom. Teva Italy will integrate Dorom's business with its own, with the combined company producing a product portfolio of 77 generic products for the Italian market and 63 generic products in the pipeline.

COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group